M
Matthew Law
Researcher at Kirby Institute
Publications - 717
Citations - 43943
Matthew Law is an academic researcher from Kirby Institute. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 89, co-authored 668 publications receiving 40044 citations. Previous affiliations of Matthew Law include Queensland University of Technology & Mahidol University.
Papers
More filters
Journal ArticleDOI
Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
Karen Schneider,Thanyawee Puthanakit,Stephen J. Kerr,Matthew Law,David A. Cooper,Basil Donovan,Nittaya Phanuphak,Virat Sirisanthana,Jintanat Ananworanich,June Ohata,David Wilson +10 more
TL;DR: Even infrequent viral load monitoring is likely to provide substantial clinical benefit to HIV-infected children on ART, and the costs associated with second-line therapies could be a barrier to its economic feasibility.
Journal ArticleDOI
A risk prediction model for the development of subsequent primary melanoma in a population-based cohort.
Anne E. Cust,Caro-Anne Badcock,Jonathan M. Smith,Nancy E. Thomas,Lauren E. Haydu,Bruce K. Armstrong,Matthew Law,John F. Thompson,P.A. Kanetsky,C. B. Begg,Yang Shi,Yang Shi,Anne Kricker,Irene Orlow,Ajay Sharma,Sarah Yoo,Siok Leong,Marianne Berwick,David W. Ollila,Serigne Lo +19 more
TL;DR: Guidelines for follow‐up of patients with melanoma are based on limited evidence and need to be reconsidered.
Journal ArticleDOI
Significance of heat-shock protein-90 as a prognostic indicator in breast-cancer.
TL;DR: A human breast cancer cDNA library was screened with a polyclonal antiserum against breast cancer metastasis membranes in order to select genes whose expression may be altered in breast malignancy and found high expression to be associated with lymph node involvement and could be a potentially useful prognostic factor and marker of aggressiveness in breast cancer.
Journal ArticleDOI
How to RESPOND to modern challenges for people living with HIV: A profile for a new cohort consortium
Ferdinand W. M. N. Wit,Peter Reiss,M. Hillebregt,Matthew Law,Kathy Petoumenos,Nectarios Rose,Jolie Hutchinson,Robert Zangerle,H. Appoyer,S De Wit,Marc Delforge,Gilles Wandeler,Christoph Stephan,M. Bucht,Nikoloz Chkhartishvili,O. Chokoshvili,A d'Arminio Monforte,A. Rodano,Alessandro Tavelli,Iuri Fanti,Cristina Mussini,Vanni Borghi,Christian Pradier,Eric Fontas,K. Dollet,C. Caissotti,Jordi Casabona,Miró Jm,A. Riera,J. Reyes-Uruena +29 more
TL;DR: RESPOND’s large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.
Journal ArticleDOI
HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia
Awachana Jiamsakul,Somnuek Sungkanuparph,Matthew Law,Rami Kantor,Jutarat Praparattanapan,Patrick C.K. Li,Praphan Phanuphak,Tuti Parwati Merati,Winai Ratanasuwan,Christopher K C Lee,Rossana Ditangco,Mahiran Mustafa,Thida Singtoroj,Sasisopin Kiertiburanakul +13 more
TL;DR: Three patterns, including thymidine analogue mutations, 69 Insertion and the Q151M complex, are associated with resistance to multiple‐nucleoside reverse transcriptase inhibitors (NRTIs) and may compromise treatment options for second‐line ART.